EGFR and squamous cell carcinoma: Similarly, another subgroup meta-analysis revealed that the OS of patients with squamous cell cancer seemed to benefit most from cetuximab (HR = 0.77, 95%CI: 0.64-0.93, P = .01).[21] Although these trials focused on different anti-EGFR-mAbs, we must consider that the benefits of cetuximab and necitumumab in the squamous cell cancer subgroup may not have been found by accident.